Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

Summary

This phase II study will evaluate the safety of combining intermediate frequency electric field (TT Field) with immunotherapy in melanoma patients with brain metastasis. The data of this study will also inform whether this combination will offer advantage in progression free survival (PFS) and overall survival.

Timeline

Start

2019-10-14

Primary completion

2020-06-08

Completion

2021-11-03

Outcome

Outcome not reported

Stopped (Enrollment): “The study was terminated early on 03/09/2022 due to low accrual during the COVID-19 pandemic.”

Drugs

Indications